Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids

Rhea-AI Summary

Kraig Biocraft Laboratories (OTCQB: KBLB) announced a significant production update for its BAM-1 spider silk hybrid strain. The new batch, the largest in the company's history, is ten times the size of the spring trials and showcases record-breaking growth and robustness in silkworms.

The production batch is a major step forward in validating the rearing protocols and demonstrating the scalability of their spider silk production technology. CEO Kim Thompson emphasized that the mission of rapidly commercializing cost-effective and environmentally responsible spider silk production is progressing towards reality. The company plans to release cocooning and processing results over the coming weeks as it targets metric ton production levels.

Positive

• Largest production batch in company history, exceeding ten times the size of previous trials.
• Record-setting growth and robustness in silkworms demonstrate the effectiveness of the BAM-1 hybrids.
• Validation of rearing protocols and operational scalability.
• Focusing on environmentally responsible spider silk production, aligning with global sustainability trends.
• CEO's confidence in the rapid commercialization of their technology.

Negative

• No specific financial data provided to indicate immediate revenue impact.
• Heavy reliance on successful scaling and commercialization, which could pose risks if targets are not met.
• Future performance largely dependent on the success of upcoming cocooning and processing results.

ANN ARBOR, Mich., June 11, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that production of its BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and robustness.

The Company announced in early June that it had accelerated its production schedule for its new BAM-1 hybrids based on the results of its spring production trials. The rearing of this first batch of production hybrids is now well underway. The Company is pleased to report that this is not only the largest single production batch in its history but also the strongest growing and most robust production batch the Company has produced.

At more than ten times the size of the spring trials, this production batch is pushing the Company's operational team to demonstrate the rapid scalability of its spider silk production technology. This production batch is validating the rearing protocols and systems put in place during the spring trials.

"Our mission has been, and will continue to be, the rapid commercialization of cost-effective and environmentally responsible spider silk production," said Company CEO and Founder, Kim Thompson. "The development of the BAM-1 hybrids and the systems we have put in place with our operations team are rapidly transitioning that mission into reality."

The Company expects to share reports on the results of the cocooning and processing of this batch of BAM-1 recombinant spider silk over the coming weeks. The Company continues to take bold moves as it aggressively moves forward, focusing on meeting its metric ton production targets.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

FAQ

What is Kraig Biocraft Laboratories' latest update on BAM-1 spider silk production?

Kraig Biocraft Laboratories reported record-breaking production of its BAM-1 spider silk hybrid strain, with the largest batch in its history and notable growth and robustness in silkworms.

How large is the new BAM-1 production batch compared to previous trials?

The new BAM-1 production batch is more than ten times the size of the spring trials, marking the largest single production in the company's history.

What are the key achievements of the BAM-1 spider silk production batch?

The BAM-1 spider silk production batch has set records for silkworm size, growth, and robustness, validating the rearing protocols and scalability of production.

When will Kraig Biocraft Laboratories share more details on the BAM-1 batch results?

Kraig Biocraft Laboratories plans to share reports on the cocooning and processing results of the BAM-1 batch over the coming weeks.

What is the long-term goal of Kraig Biocraft Laboratories with its BAM-1 spider silk production?

The long-term goal is the rapid commercialization of cost-effective and environmentally responsible spider silk production, aiming to meet metric ton production targets.